Back to All Events

University of Kansas Cancer Center Breast Cancer Year in Review

  • Marriott Kansas City Overland Park 10800 Metcalf Avenue Overland Park, KS, 66210 United States (map)

In-Person Access Only | 4.00 CE/CME Credits

The University of Kansas Cancer Center Breast Cancer Year in Review is a condensed review of new data and advances published throughout the year and presented at key oncology meetings. It gives healthcare providers the opportunity to learn about the latest advances in oncology education and translate science into better patient care. This accredited meeting is hosted as an in-person conference only with on-demand access for registered attendees

Angela DeMichele, MD, MSCE, FASCO | Abramson Cancer Center, University of Pennsylvania

Ana Garrido-Castro, MD | Dana-Farber Cancer Institute, Harvard Medical School

Matthew Goetz, MD | Mayo Clinic 

 

Conference Agenda
Saturday, February 22, 2025

8:35 AM
Welcome and Exhibits

8:55 AM
Opening Remarks

9:00 AM
Non CME Presentation

9:45 AM
Adjuvant Systemic Therapy for HR+ Breast Cancer: Which Agents, When, and For How Long? Matthew Goetz, MD | Mayo Clinic 

10:10 AM
Metabolic syndrome and obesity in breast cancer: Key signaling pathways and Impact on sensitivity to therapy Kristy A. Brown, PhD | University of Kansas Cancer Center 

10:35 AM
Break and Exhibits

10:55 AM
Optimizing use of available antibody drug conjugates for metastatic breast cancer Ana Garrido-Castro, MD | Dana-Farber Cancer Institute, Harvard Medical School

11:20 AM
Monday morning Ptacice Implications: Q&A and Case Discussion Ana Garrido-Castro, MD | Dana-Farber Cancer Institute, Harvard Medical School Matthew Goetz, MD | Mayo Clinic  Kristy A. Brown, PhD | University of Kansas Cancer Center 

12:05 PM
Break and Exhibits

12:15 PM
Non CME Presentation

1:00 PM
Immune related toxicities of Chemoimmunotherapy in early-stage breast cancer: risk stratification, management and future directions Angela DeMichele, MD, MSCE, FASCO | Abramson Cancer Center, University of Pennsylvania

1:25 PM
Systemic treatment of Stage I Hormone negative breast cancer:  Optimal regimens, timing and duration 

1:50 PM
Break and Exhibits

2:00 PM
Advanced Stage Hormone Positive Breast Cancer: Fine-Tuning Sequential Endocrine and Targeted Therapy

2:25 PM
Monday morning Ptacice Implications: Q&A and Case Discussion Angela DeMichele, MD, MSCE, FASCO | Abramson Cancer Center, University of Pennsylvania

3:10 PM
Adjourn

Agenda Subject To Change. All times are CST.

 
    • Determine best application of new targeted therapies in patients with early stage and metastatic disease

    • Discuss the advances in systemic therapy likely to change current practices for treatment of breast cancer

    • Know how to utilize genomic tools for systemic therapy decision making and prediction of treatment response.

    • Be familiar with germ-line genetic testing options for hereditary breast cancer, including advantages and disadvantages of extended panel testing

    • Evaluate local therapy options for operable breast cancer depending on stage, and the use of neoadjuvant therapy

    • Identify evidence-based recommendations for decreasing symptoms and improving quantity and/or quality of life in survivors

  • In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Nurses (ANCC) Credit Designation

    Amedco LLC designates this activity for a maximum of TBD ANCC contact hours.

    Physicians (ACCME) Credit Designation

    Amedco LLC designates this live activity for a maximum of 4.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

    Amedco LLC designates this activity for a maximum of 4.00 knowledge-based CPE contact hours.

    NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

    • Free registration for all healthcare providers

    • Expert sessions that present the most clinically relevant data, research, and clinical strategies

    • Real-time discussion and debate

    • Networking with peers, colleagues, and medical professionals

    • Access to the latest industry information and resources

    • Catered meals through-out the program

 
Previous
Previous
February 8

West Oncology Conference

Next
Next
February 27

Cancer Updates GI and Breast